<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080987</url>
  </required_header>
  <id_info>
    <org_study_id>CR108306</org_study_id>
    <secondary_id>2016-004785-25</secondary_id>
    <secondary_id>64179375EDI1002</secondary_id>
    <nct_id>NCT03080987</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Japanese Participants</brief_title>
  <official_title>A 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety and tolerability of JNJ-64179375
      in Part 1 and 2.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 3, 2017</start_date>
  <completion_date type="Anticipated">December 7, 2017</completion_date>
  <primary_completion_date type="Anticipated">December 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 113</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 113</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Maximum Observed Plasma Concentration (Cmax) of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>Cmax is the maximum observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>The AUC (0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>The AUC (0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Total Systemic Clearance (CL) of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>CL is defined as total systemic clearance after intravenous administration of JNJ-64179375.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent Volume of Distribution at Terminal Phase After Intravenous Administration (Vz) of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>Vz is defined as the Apparent volume of distribution at terminal phase after intravenous administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Terminal Half-Life (t1/2) of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>Half-life is the time measured for the plasma concentration of drug to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Total Systemic Clearance Over Bioavailability After Subcutaneous (SC) Administration (CL/F) of JNJ-64179375 post-dose</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>CL/F is defined as total systemic clearance over bioavailability after SC administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Volume of Distribution at Terminal Phase Over Bioavailability After Subcutaneous Administration (Vz/F) of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>(Vz/F) is defined as Apparent Volume of distribution at terminal phase over bioavailability after SC administration of JNJ-64179375.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Absolute Bioavailability (F) After Subcutaneous Administration of JNJ-64179375</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 10, 14, 22, 29, 43, 57, 85 and 113 post-dose</time_frame>
    <description>F is defined as absolute bioavailability after SC administration of JNJ-64179375.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Immunogenicity of JNJ-64179375</measure>
    <time_frame>Predose, Day 7, 14, 29, 57, 85 and 113 post-dose</time_frame>
    <description>Plasma samples will be collected and screened for antibodies binding to JNJ-64179375 and the titer of confirmed positive samples will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 as Assessed by Change in Thrombin Time (TT)</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 14, 29, 57 and 113 post-dose</time_frame>
    <description>The pharmacodynamic effect of JNJ-64179375 on coagulation parameters will be assessed by measuring the change in thrombin time (TT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 as Assessed by Change in Prothrombin Time (PT)</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 14, 29, 57 and 113 post-dose</time_frame>
    <description>The pharmacodynamic effect of JNJ-64179375 on coagulation parameters will be assessed by measuring the change in prothrombin time (PT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 as Assessed by Change in Activated Partial Thromboplastin time (aPTT)</measure>
    <time_frame>Predose, Day 1, 2, 4, 7, 14, 29, 57 and 113 post-dose</time_frame>
    <description>The pharmacodynamic effect of JNJ-64179375 on coagulation parameters will be assessed by measuring the change in activated partial thromboplastin time (aPTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 as Assessed by Change in Ecarin Clotting time (ECT)</measure>
    <time_frame>Predose, Day 1, 2, 4, and 14 post-dose</time_frame>
    <description>The pharmacodynamic effect of JNJ-64179375 on coagulation parameters will be assessed by measuring the change in Ecarin Clotting time (ECT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 on Platelet Function</measure>
    <time_frame>Predose, Days 1 and 14 post-dose</time_frame>
    <description>Platelet function will be assessed by measuring platelet activation and aggregation in response to thrombin and other agonists and with the platelet function analyzer (PFA)100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 as Assessed by Hemoclot Thrombin Inhibitor Assay</measure>
    <time_frame>Predose, Day 1, 2, 4, and 14 post-dose</time_frame>
    <description>Hemoclot Thrombin Inhibitor assay is a clotting assay that provides a quantitative measurement of direct thrombin inhibitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 as Assessed by Thrombin Generation Assay (TGA)</measure>
    <time_frame>Predose, Day 1 and 14 post-dose</time_frame>
    <description>The TGA is based on the premise that measurements of thrombin generation are indicative of the overall coagulating capacity of the individual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and 2: Pharmacodynamic Effect of JNJ-64179375 as Assessed by D-dimer</measure>
    <time_frame>Predose, Day 1 and 14 post-dose</time_frame>
    <description>The D-dimer assay is an enzyme immunoassay procedure for the quantitative determination of D-dimer.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.3 milligram per kilogram (mg/kg) intravenous (IV) dose of JNJ-64179375 or matching Placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 1.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 2.5 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 4 (5.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 5.0 mg/kg IV dose of JNJ-64179375 or matching Placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single IV dose of JNJ-64179375 (dose to be determined) or matching Placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375 or matching Placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64179375 0.3 mg/kg</intervention_name>
    <description>JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.</description>
    <arm_group_label>Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64179375 1.0 mg/kg</intervention_name>
    <description>JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).</description>
    <arm_group_label>Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64179375 2.5 mg/kg</intervention_name>
    <description>JNJ-64179375 2.5 mg/kg IV infusion on Day 1.</description>
    <arm_group_label>Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64179375 5.0 mg/kg</intervention_name>
    <description>JNJ-64179375 5.0 mg/kg IV infusion on Day 1.</description>
    <arm_group_label>Part 1: Cohort 4 (5.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).</description>
    <arm_group_label>Part 1: Cohort 1 (0.3 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 1: Cohort 2 (1.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 1: Cohort 3 (2.5 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 1: Cohort 4 (5.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 2: SC Cohort (1.0 mg/kg of JNJ-64179375 or Placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64179375 (Dose to be Determined)</intervention_name>
    <description>JNJ-64179375 IV infusion (Dose to be determined).</description>
    <arm_group_label>Part 1: Optional Cohort 1 (JNJ-64179375 or Placebo)</arm_group_label>
    <arm_group_label>Part 1: Optional Cohort 2 (JNJ-64179375 or Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have been born in Japan of Japanese parents and maternal and paternal Japanese
             grandparents

          -  Body mass index (weight kg/m^2) between 18 and 27 kilogram per square meter (kg/m^2)
             (inclusive), and body weight greater than 50 kg but less than 100 kg

          -  Generally in good health on the basis of physical examinations, medical history,
             vital signs, laboratory tests, electrocardiograms (ECGs) and cardiac telemetry
             performed at Screening and/or prior to administration of the initial dose of study
             drug

          -  Must sign an informed consent form (ICF) indicating that he understands the purpose
             of, and procedures required for, the study and is willing to participate in the study

        Exclusion Criteria:

          -  History of or current clinically significant medical illness including (but not
             limited to) cardiac arrhythmias or other cardiac disease, hematologic disease,
             bleeding or thrombotic disorders (including any personal or family history of
             abnormal bleeding as assessed by a detailed bleeding history or blood dyscrasias), or
             with an underlying coagulopathy that may lead to a clinically relevant bleeding risk,
             autoimmune disease, lipid abnormalities, significant pulmonary disease, including
             bronchospastic respiratory disease, diabetes mellitus, renal or hepatic
             insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any
             other illness that the investigator considers should exclude the subject or that
             could interfere with the interpretation of the study results

          -  Acute illness, including an upper respiratory infection (with or without fever),
             within 7 days prior to study drug administration or have had a major illness or
             hospitalization within 1 month prior to study drug administration

          -  Clinically significant abnormal physical exam at Screening or Day -1

          -  Clinically significant abnormal vital signs at Screening, Day -1, or Day 1 (predose)
             as determined by the investigator or appropriate designee

          -  Clinically significant abnormal 24-hour Holter electrocardiogram (ECG), cardiac
             telemetry, or ECG at Screening, Day -1, or Day 1 (predose) as determined by the
             investigator or appropriate designee
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This study is not yet recruiting patients. Please check back for future recruiting sites, or email</last_name>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Richmond Pharmacology Ltd</name>
      <address>
        <city>Surrey</city>
        <zip>CR7 7YE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>March 10, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
